Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy

Cancer Cell

Volumn 12, Issue 1, 2007, Pages 81-93

  Li, Danan ^a   Shimamura, Takeshi ^a,d   Ji, Hongbin ^a   Chen, Liang ^a   Haringsma, Henry J ^a   McNamara, Kate ^a   Liang, Mei Chih ^a   Perera, Samanthi A ^a   Zaghlul, Sara ^a   Borgman, Christa L ^a   Kubo, Shigeto ^b   Takahashi, Masaya ^b   Sun, Yanping ^c   Chirieac, Lucian R ^c   Padera, Robert F ^c   Lindeman, Neal I ^c   Jänne, Pasi A ^a,d   Thomas, Roman K ^e,f   Meyerson, Matthew L ^a,g   Eck, Michael J ^a   Engelman, Jeffrey A ^d   Shapiro, Geoffrey I ^a,d   Wong, Kwok Kin ^a,d   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

CELLCYCLE; CHEMBIO; SIGNALING

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; HKI 272; RAPAMYCIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DEFENSE MECHANISM; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; LUNG TUMOR; MOUSE; MUTATION; NONHUMAN; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

MURINAE;

EID: 34347208648     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.06.005     Document Type: Article

References (33)

1. Bell D.W., Gore I., Okimoto R.A., Godin-Heymann N., Sordella R., Mulloy R., Sharma S.V., Brannigan B.W., Mohapatra G., Settleman J., and Haber D.A. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 37 (2005) 1315-1316
2. Buck E., Eyzaguirre A., Brown E., Petti F., McCormack S., Haley J.D., Iwata K.K., Gibson N.W., and Griffin G. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 5 (2006) 2676-2684
3. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97 (2005) 643-655
4. Conde E., Angulo B., Tang M., Morente M., Torres-Lanzas J., Lopez-Encuentra A., Lopez-Rios F., and Sanchez-Cespedes M. Molecular context of the EGFR mutations: Evidence for the activation of mTOR/S6K signaling. Clin. Cancer Res. 12 (2006) 710-717
5. Easton J.B., Kurmasheva R.T., and Houghton P.J. IRS-1: Auditing the effectiveness of mTOR inhibitors. Cancer Cell 9 (2006) 153-155
6. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., and Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 102 (2005) 3788-3793
7. Engelman J.A., and Cantley L.C. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 12 (2006) 4372s-4376s
8. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borras A.M., Gale C.M., Naumov G.N., Yeap B.Y., Jarrell E., Sun J., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116 (2006) 2695-2706
9. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., and Varmus H.E. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15 (2001) 3249-3262
10. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 (2005) 179-183
11. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
12. Ji H., Li D., Chen L., Shimamura T., Kobayashi S., McNamara K., Mahmood U., Mitchell A., Sun Y., Al-Hashem R., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9 (2006) 485-495
13. Ji H., Zhao X., Yuza Y., Shimamura T., Li D., Protopopov A., Jung B.L., McNamara K., Xia H., Glatt K.A., et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. USA 103 (2006) 7817-7822
14. Johnson B.E., Jackman D., and Janne P.A. Impact of EGFR mutations on treatment of non-small cell lung cancer. Cancer Chemother. Pharmacol. 58 Suppl 7 (2006) 5-9
15. Kato J.Y., Takeya T., Grandori C., Iba H., Levy J.B., and Hanafusa H. Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein. Mol. Cell. Biol. 6 (1986) 4155-4160
16. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., Crowley D., Bronson R.T., and Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121 (2005) 823-835
17. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
18. Kobayashi S., Ji H., Yuza Y., Meyerson M., Wong K.K., Tenen D.G., and Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65 (2005) 7096-7101
19. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102 (2005) 7665-7670
20. Li D., Ji H., Zaghlul S., McNamara K., Liang M.C., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., Padera R.F., et al. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J. Clin. Invest. 117 (2007) 346-352
21. Manning B.D. Balancing Akt with S6K: Implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167 (2004) 399-403
22. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66 (2006) 1500-1508
23. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 (2005) e73 10.1371/journal.pmed.0020073
24. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., and Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20 (2006) 1496-1510
25. Riely G.J., Politi K.A., Miller V.A., and Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12 (2006) 7232-7241
26. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., and Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445 (2007) 437-441
27. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353 (2005) 123-132
28. Shigematsu H., and Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 118 (2006) 257-262
29. Shimamura T., Lowell A.M., Engelman J.A., and Shapiro G.I. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 65 (2005) 6401-6408
30. Shimamura T., Ji H., Minami Y., Thomas R.K., Lowell A.M., Shah K., Greulich H., Glatt K.A., Meyerson M., Shapiro G.I., and Wong K.K. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 66 (2006) 6487-6491
31. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 16 (2005) 525-537
32. Vogt P.K. PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol. Med. 7 (2001) 482-484
33. Zhang X., Gureasko J., Shen K., Cole P.A., and Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006) 1137-1149